Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.

Journal of medical economics

Volumn 16, Issue 2, 2013, Pages 202-212

  Barzey, Victor ^a   Atkins, Michael B ^b   Garrison, Louis P ^b   Asukai, Yumi ^b   Kotapati, Srividya ^b   Penrod, John R ^b  

^a IQVIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; HUMAN; MEDICAL AUDIT; MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; HUMANS; MARKOV CHAINS; MEDICAL AUDIT; MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84879021680     PISSN: None     EISSN: 1941837X     Source Type: None    
DOI: 10.3111/13696998.2012.739226     Document Type: Article

References (0)